Kodiak Sciences Inc.: management transactions · United States · SEC (Form 4)

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq in the United States. The company is focused on researching, developing, and, ultimately, commercializing transformative retinal therapies. Founded in 2009, Kodiak has positioned itself as a retina-focused, science-driven biotech operating in one of the most competitive yet medically important segments of ophthalmology. Its strategy is anchored in addressing major unmet needs in retinal disease, an area where better durability, improved efficacy, and more convenient dosing remain key differentiators versus existing standards of care. Kodiak describes itself as a precommercial company, meaning it is still in the clinical-development stage and has not yet built a broad marketed product franchise. The core of its scientific platform is the ABC technology, which the company uses to design next-generation retinal medicines with the goal of combining strong biological activity with longer duration of effect. Kodiak’s most closely watched programs include KSI-501, KSI-101, and tarcocimab, each aimed at high-value retinal indications and designed to compete in disease areas with significant clinical unmet need. In practical terms, the company’s value proposition rests on whether these assets can deliver meaningful advantages in efficacy, durability, or treatment burden versus current therapies. From a competitive standpoint, Kodiak operates in a field dominated by larger pharmaceutical companies and well-funded ophthalmology specialists. That makes clinical differentiation especially important. Success depends not only on scientific novelty, but also on clean safety data, reproducible efficacy, and the ability to translate platform science into commercially meaningful products. Kodiak’s pipeline-centric model also means that investor attention is heavily concentrated on clinical milestones, regulatory progress, and data readouts rather than near-term product sales. Geographically, Kodiak is headquartered in the United States and is part of the U.S. public-market biotech ecosystem, with reporting and disclosure obligations under SEC rules. Recent company updates show an active capital-markets and development agenda, including equity financings in 2025 and early 2026, as well as recurring business updates tied to pipeline advancement. Kodiak has indicated that its three Phase 3 assets are on track for topline data in 2026, making that year potentially decisive for the company’s long-term trajectory. For investors, Kodiak Sciences remains a high-risk, high-upside specialty biotech story tied to retina innovation, clinical execution, and the ability to convert platform science into durable competitive advantage.